Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer
Open Access
- 1 January 2008
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 3 (1), 30-36
- https://doi.org/10.1097/jto.0b013e31815e8b48
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice GuidelineJournal of Thoracic Oncology, 2006
- Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21Journal of Clinical Oncology, 2006
- Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapyJournal of Clinical Oncology, 2006
- Second-line treatment for advanced non-small cell lung cancer: A systematic reviewLung Cancer, 2006
- Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxelJournal of Clinical Oncology, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Evaluating clinical versus statistical significance with the LCSS quality of life instrument and the Karnofsky Performance Status (KPS)Lung Cancer, 2000
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal Of Cancer, 1993
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992